Assessment of Vertigo and Dizziness in Individuals Following COVID-19

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06871280

Enrollment

296

Registered

2025-03-11

Start date

2021-06-01

Completion date

2021-12-31

Last updated

2025-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

This cross-sectional study aimed to assess the prevalence of dizziness/vertigo in individuals following COVID-19 and to investigate potential risk factors associated with these symptoms. A total of 296 patients aged 20-66 years who had recovered from COVID-19 were evaluated at Istanbul Physical Medicine and Rehabilitation Training and Research Hospital between June 1, 2021, and December 31, 2021. Clinical and demographic data, including COVID-19 history, comorbidities, and symptom characteristics, were collected. Dizziness-related disability was assessed using the Dizziness Handicap Inventory (DHI), while balance performance was evaluated with the Berg Balance Scale (BBS).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

20 Years to 66 Years

Inclusion criteria

* Individuals aged 20-66 years. * History of confirmed COVID-19 infection. * Ability to speak and understand Turkish. * Willingness to provide verbal and written informed consent.

Exclusion criteria

* Pre-existing vertigo or balance disorders (e.g., benign paroxysmal positional vertigo, Ménière's disease, vestibular migraine, vestibular neuritis). * Inner ear diseases or vestibular dysfunction. * Neurological disorders affecting balance (e.g., multiple sclerosis, Parkinson's disease, history of stroke, epilepsy). * Psychiatric conditions that could cause dizziness (e.g., anxiety, panic attacks, depression). * History of head or neck trauma in the past six months. * Moderate to severe visual impairment. * Chronic alcohol or substance use. * Use of ototoxic medications. * Severe cardiovascular diseases (e.g., orthostatic hypotension, advanced heart failure, severe arrhythmias). * Pregnant or breastfeeding women. * Acute infection other than COVID-19 in the past three months. * Severe COVID-19 requiring hospitalization

Design outcomes

Primary

Measure	Time frame	Description
Dizziness Handicap Inventory	0 day	Prevalence of dizziness/vertigo in individuals following COVID-19, assessed using the Dizziness Handicap Inventory (DHI). Range: 0-100 (Higher scores indicate greater dizziness-related disability).

Secondary

Measure	Time frame	Description
Berg Balance Scale (BBS)	0 day	Balance status evaluated using the Berg Balance Scale (BBS). Range: 0-56 (Higher scores indicate better balance)

Countries

Turkey (Türkiye)

Outcome results